Therefore the CPMP considered that the benefit/ risk balance of the combination of loratadine and pseudoephedrine containing medicinal products remains unchanged for the indication “ symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion” and recommended the maintenance of the Marketing Authorisations according to the Summary of Product Characteristics as set out in Annex III of the CPMP Opinion with emphasis to the following: